Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Xencor Inc (NASDAQ: XNCR) today and set a price target of $45. The company’s shares opened today at $40.63, close to its 52-week high of $44.88.
According to TipRanks.com, Lee is a 1-star analyst with an average return of 0.0% and a 41.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xencor Inc with a $47.50 average price target, representing a 16.9% upside. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $52 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44.88 and a one-year low of $18.97. Currently, Xencor Inc has an average volume of 301.6K.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.
